Weichyun Wong, president of SCI Pharmtech, discusses the API manufacturer’s transition from a Swiss-owned affiliate to a Taiwanese company. He also talks technology and regulatory challenges, as well as what differentiates SCI Pharmtech from its competitors.
SCI Pharmtech, Inc. has a long-standing presence in Taiwan. Could you tell us a bit about SCI’s recent history and how Swiss heritage contributes to the company’s success today?
"Referring to the Swiss heritage, I believe it is very beneficial for the company, as we were trained by Swiss system that taught us how to be efficient and achieve extraordinary results."
